Appili Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference
27 Abril 2022 - 8:37AM
Business Wire
Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the “Company”
or “Appili”), a biopharmaceutical company focused on drug
development for infectious diseases, today announced that Stéphane
Paquette, Vice President, Corporate Development, will present at
the Bloom Burton & Co. Healthcare Investor Conference taking
place on May 2 and 3, 2022.
The presentation will include an update on Appili’s pipeline of
novel anti-infectives and highlight recent progress, such as
working with the US Department of Defense to expand non-dilutive
funding for biodefense vaccine candidate ATI-1701 and growing
Appili’s pipeline via the licensing of late-stage clinical program
ATI-1801 for the treatment of cutaneous leishmaniasis.
Presentation details are as follows:
Date: Tuesday, May 3, 2022 Time: 3:00 pm ET
Location: Metro Toronto Convention Centre, 255 Front St W,
Toronto, Ontario
Appili management will also be conducting one-to-one meetings
throughout the conference. To request a one-to-one meeting, please
register for the conference here.
About Appili Therapeutics Appili Therapeutics is an infectious
disease biopharmaceutical company that is purposefully built,
portfolio-driven, and people-focused to fulfill its mission of
solving life-threatening infections. By systematically identifying
urgent infections with unmet needs, Appili’s goal is to
strategically develop a pipeline of novel therapies to prevent
deaths and improve lives. The Company is currently advancing a
diverse range of anti-infectives, including a broad-spectrum
antifungal, a vaccine candidate to eliminate a serious biological
weapon threat, a topical antiparasitic product for the treatment of
a disfiguring disease, and two novel antibiotic programs. Led by a
proven management team, Appili is at the epicenter of the global
fight against infection. For more information, visit
www.AppiliTherapeutics.com.
About Bloom Burton & Co.: Bloom Burton & Co. is a
firm dedicated to accelerating returns in the healthcare sector for
both investors and companies. Bloom Burton has an experienced team
of medical, scientific, pharmaceutical, legal and capital markets
professionals who perform a deep level of diligence, which combined
with our creative and entrepreneurial approach, assists our clients
in achieving the right monetization events. Bloom Burton and its
affiliates provide capital raising, M&A advisory, equity
research, business strategy and scientific consulting, advisory on
direct investing and company creation and incubation services.
Bloom Burton Securities Inc. is a member of the Investment Industry
Regulatory Organization of Canada (IIROC) and is also a member of
the Canadian Investor Protection Fund (CIPF).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220426006338/en/
Media: Danielle Raabe/APCO Worldwide 1-646-717-9915
DRaabe@apcoworldwide.com
Investor Relations: Stéphane Paquette; Vice President,
Corporate Development Appili Therapeutics
Info@AppiliTherapeutics.com
Appili Therapeutics (TSX:APLI)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Appili Therapeutics (TSX:APLI)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024